Towa Pharmaceutical Co Ltd 2023 IR
The report highlights Towa Pharmaceutical's efforts to enhance corporate value through stable supply of generics, human capital management, and environmental initiatives. It details the company's value creation process and the 5th Mid-term Business Plan 2021-2023. The report also covers the company's financial and non-financial performance, including production capacity expansion and sustainability efforts. The company aims to be a comprehensive healthcare company for the era of the 100-year life.
Company: Towa Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2023
Type: IR
Pages: 58
Towa Pharmaceutical Co Ltd
Integrated Report
The report highlights Towa Pharmaceutical's efforts to enhance corporate value through stable supply of generics, human capital management, and environmental initiatives. It details the company's value creation process and the 5th Mid-term Business Plan 2021-2023. The report also covers the company's financial and non-financial performance, including production capacity expansion and sustainability efforts. The company aims to be a comprehensive healthcare company for the era of the 100-year life.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Apr 1, 2022 - Mar 31, 2023
Fiscal Year
2022
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
No data available